Skip to main content
Pangen Biotech Inc. logo

Pangen Biotech Inc. — Investor Relations & Filings

Ticker · 222110 ISIN · KR7222110009 KO Manufacturing
Open in API
Filings indexed 333 across all filing types
Latest filing 2020-11-19 Regulatory Filings
Country KR South Korea
Listing KO 222110

About Pangen Biotech Inc.

https://pangen.com/layout/eng/home.php

Pangen Biotech Inc. is a biotechnology company specializing in the research, development, and manufacturing of biopharmaceuticals. The company utilizes its proprietary platform technologies, particularly those based on Chinese Hamster Ovary (CHO) cell lines, for the production of complex protein therapeutics. Its primary business activities include the development of a pipeline of biosimilar products, such as Erythropoietin (EPO) and Aflibercept. In addition to its own product pipeline, Pangen Biotech offers Contract Development and Manufacturing Organization (CDMO) services, providing expertise in cell line development and biopharmaceutical production to other firms. The company also supplies reagents and kits for research applications.

Recent filings

Filing Released Lang Actions
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) by the company Pangen. It details the contract amount, the counterparty (Duopharma), the contract period, and the nature of the supply (pharmaceutical raw materials). Since this is a specific regulatory disclosure regarding a commercial contract that does not fit into the other specialized categories like M&A or financial reports, it is classified as a general regulatory filing.
2020-11-19 Korean
분기보고서 (2020.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company 'PanGen' covering the period from 2020.01.01 to 2020.09.30. It contains detailed financial information, business descriptions, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-13 Korean
투자판단관련주요경영사항(A형 혈우병 치료제 PGA40의 국내 임상 1상 시험 결과(임상시험결과보고서 수령))
Legal Proceedings Report Classification · 95% confidence The document is a formal regulatory disclosure filed by Pangen regarding the results of a Phase 1 clinical trial for their hemophilia A treatment, PGA40. It details the trial methodology, safety, efficacy, and future plans for Phase 3 trials. As this is a specific regulatory announcement regarding material business developments (clinical trial results) that does not fit into categories like financial reports, dividends, or M&A, it falls under the general regulatory filing category.
2020-11-04 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Amendment Report) to a previous filing. It details changes to the number of stock options granted, the number of recipients, and the total outstanding options due to employee departures. This type of disclosure regarding stock option grants and subsequent amendments falls under general regulatory filings in the context of corporate governance and capital structure updates.
2020-11-03 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when an insider (director or major shareholder) trades company shares. This falls under the category of 'Director's Dealing' (DIRS), which covers insider transactions.
2020-10-16 Korean
기타경영사항(특허권취득)(자율공시)(인간 및 마우스 Sema3A에 교차 결합하는 항체 및 그의 용도)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure from a Korean company (Pangen) regarding the acquisition of a patent. It follows the standard format for 'Other Management Matters' (자율공시), which is a voluntary disclosure of significant corporate events. Since it does not fit into specific categories like financial reports, dividends, or management changes, it falls under the general regulatory filing category.
2020-09-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.